SVB Leerink Downgrades Calithera Biosciences to Market Perform, Lowers Price Target to $2
Benzinga Real-time NewsNov 15, 2022 04:08 ET
Calithera Biosciences Price Target Announced at $8.00/Share by HC Wainwright & Co.
Dow JonesAug 29, 2022 06:22 ET
HC Wainwright Upgrades Calithera Biosciences to Buy From Neutral; Price Target Is $8
MT NewswiresAug 29, 2022 06:12 ET
Calithera Biosciences Is Maintained at Outperform by SVB Leerink
Dow JonesAug 16, 2022 12:08 ET
Calithera Biosciences Price Target Raised to $18.00/Share From $2.00 by SVB Leerink
Dow JonesAug 16, 2022 12:08 ET
SVB Leerink Maintains Outperform on Calithera Biosciences, Raises Price Target to $18
Benzinga Real-time NewsAug 16, 2022 11:58 ET
No Data
No Data